MedTrace Logo

Symptomatic Therapy for Patients With Huntington's Disease

NCT04071639 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-04-02

No results posted yet for this study

Summary

Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.

Conditions

  • Huntington Disease

Interventions

DRUG

Haloperidol 2Mg Tab

Haloperidol take 0.5mg\~2mg three time a day.

DRUG

Risperidone 1Mg Tab

Risperidone take 1mg once at night.

DRUG

Zoloft 50Mg Tablet

Zoloft take 50mg once in the morning.

DRUG

Idebenone

Idebebone take 30mg three times a day.

DRUG

Deutetrabenazine Oral Tablet [Austedo]

The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.

Sponsors & Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Zhi-Ying Wu · Second affiliated Hospital, Zhejiang University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04071639 on ClinicalTrials.gov